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PODIUM SESSION III:
INFECTIOUS DISEASE OUTCOMES RESEARCH
IN1
ANTIBIOTIC PRESCRIBING VIA TELEPHONE: HOW OFTEN DOES IT OCCUR?
Willey VJ1, Ewen E2, Vichaichanakul K1, Khole T1, Dabeer P1, Loka N1, Mcghan WF1,
Drees M2
1University of the Sciences, Philadelphia, Philadelphia, PA, USA, 2Christiana Care, Newark, DE,
USA
OBJECTIVES: Antibiotic prescribing via telephonemay be associated with inappro-
priate antibiotic use and potential bacterial resistance, although limited data exist
regarding this practice. The purpose of this analysiswas to examine the prevalence
and patterns of telephone antibiotic prescribing. METHODS: Patients’ antibiotic
prescription data were retrieved from a large, Mid-Atlantic health system outpa-
tient electronic medical record from 2006-2010. Antibiotic prescriptions were cat-
egorized as initiated by telephone or office visit and by antibiotic classifications;
antibiotics for chronic usewere excluded. Practiceswere categorized as teaching or
private. Annual number of patients was calculated as a three-year running average
and patient data were censored on date of death, date of last activity plus 24
months, or January 1, 2011, whichever came earliest. Rates of telephone antibiotic
prescribing were calculated and stratified by practice type and antibiotic
classification. RESULTS: The analysis included 219,282 patient-years (pt-yrs), dur-
ing which 64,193 antibiotic prescriptions were generated. Overall antibiotic pre-
scribingwas 29.3/100 pt-yrs; 12.4% of the antibiotics were prescribed via telephone,
although 39.0% of these “telephone-antibiotic” patients had an office visit in the
prior 7 days. Antibiotic prescribing overall and via telephone was greater in private
practices (34.7/100 pt-yrs and 14.0%) compared with teaching practices (20.6/100
pt-yrs and 8.0%) (both P0.05). Macrolides (25.4%) and beta-lactams (22.9%) were
the most commonly prescribed antibiotic classes overall with macrolides and
quinolones most common via telephone. Approximately one-fifth of quinolone
prescriptions (20.1%) were prescribed via telephone, including 16.6% for newer
quinolones (levofloxacin or moxifloxacin). CONCLUSIONS: Prescribing via tele-
phone occurred in approximately one in eight antibiotic prescriptions and varied
by practice type and antibiotic classification. Significant numbers of prescriptions
for newer, broad spectrum antibiotics were generated telephonically. The fre-
quency and prescribing patterns associated with telephone antibiotic prescribing
in this population support the need for further study of its impact on antibiotic
resistance.
IN2
COMPARATIVE EFFICACY AT 48 WEEKS OF ATAZANAVIR/RITONAVIR VERSUS
DARUNAVIR/RITONAVIR IN TREATMENT NAIVE HIV-1 PATIENTS: A MATCHING
ADJUSTED INDIRECT COMPARISON OF RANDOMIZED TRIALS
Xie J1, Juday T2, Swallow E1, Du X1, Uy J2, Hebden T2, Signorovitch J1
1Analysis Group, Inc., Boston, MA, USA, 2Bristol-Myers Squibb Company, Plainsboro, NJ, USA
OBJECTIVES: No large, randomized head-to-head comparison of atazanavir/
ritonavir (ATV/r) and darunavir /ritonavir (DRV/r) for first-line treatment of HIV-1 is
currently available. This study compares the efficacy of ATV/r and DRV/r at 48
weeks using a matching-adjusted indirect comparison. METHODS: Two similarly
designed randomized trials were identified. Individual patient-level data were
available for the CASTLE trial comparing ATV/r (n430) vs. lopinavir/r (LPV/r)
(n438), each in combination with tenofovir/emtricitabine (TDF/FTC); published
summary data were used from the ARTEMIS trial comparing DRV/r (n343) vs.
LPV/r (n346), each in combination with TDF/FTC. To adjust for cross-trial differ-
ences, CASTLE patients were re-weighted to match summary baseline character-
istics in ARTEMIS. The primary endpoint was virologic response (HIV-1 RNA50
copies/mL) at 48 weeks assessed using time to loss of virologic response (TLOVR),
and was compared between balanced ATV/r and DRV/r trial populations after
matching. As a negative control, outcomes in the two LPV/r arms were compared.
RESULTS: Data from all patients in the two trials were included. Before matching,
baseline characteristics differed significantly between CASTLE and ARTEMIS. CAS-
TLE had a higher proportion of patients with HIV-1 RNA100,000 copies/mL, a
lower proportion with CDC class C, and lower median CD4 cell count. Without
matching, a naïve comparison showed ATV/r-treated patients had a significantly
lower virologic response rate at week 48 than DRV/r-treated patients (78% vs. 84%,
p0.040). After matching, mean baseline characteristics were exactly balanced
between CASTLE and ARTEMIS, and virologic response to LPV/r was comparable
(77% vs. 78%, p0.811). There was no significant difference between ATV/r and
DRV/r in virologic response rate (80% vs. 84%, p0.138). CONCLUSIONS: After ad-
justing for cross-trial differences in baseline characteristics, the analysis suggests
that ATV/r and DRV/r, each in combination with TDF/FTC, are equally efficacious.
A randomized head-to-head trial will provide the gold standard of the comparative
efficacy between the two treatments.
IN3
TRANSLATING OUTCOMES FROM A DYNAMIC TRANSMISSION MODEL FOR
VARICELLA VACCINATION TO COST-EFFECTIVENESS ESTIMATES: THE IMPACT
OF DIFFERENT ANALYTIC APPROACHES ON THE RESULTS
Thompson JR1, Talbird SE1, Mauskopf JA1, Brogan A1, Standaert B2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2GlaxoSmithKline Biologicals, Wavre,
Belgium
OBJECTIVES: Compare three different analytic approaches to estimate the cost-
effectiveness of a varicella vaccination programme using clinical outcomes from a
dynamic transmission model. METHODS: An age-structured SIR (susceptible, in-
fectious, recovered) dynamic transmission model was developed to predict the
impact of routine infant vaccination on varicella incidence. Individuals transi-
tioned between S and I compartments based on UK force-of-infection data. Each
compartmentwas stratified into 8 age groups to track individuals as they aged over
time. Input parameters including force of infection, who-acquires-infection-from-
whom (WAIFW)matrix structure, vaccine efficacy, vaccine coverage, costs, QALYs,
and demographic data were based on published UK data. Themodel estimated the
incremental cost-effectiveness ratio (ICER) for the vaccination programme using
three analytic approaches: summing outcomes 1) for the entire population cumu-
latively over time (CumPop), 2) for the entire population for the steady-state year
(SSPop), and 3) for the lifetime of the first vaccinated birth cohort (Cohort). Costs
and QALYs were discounted at 3.5% per year. ICERs were compared for the three
analyses for different time horizons and vaccine coverage rates. RESULTS: The
vaccination programme reached a steady state after 75 years. For this timehorizon,
the incremental costs per QALY gained for the CumPop (£1,407) and SSPop (£868)
analyses were 47% and 68% lower than for the Cohort (£2,678) analysis. In the
CumPop and Cohort analyses, the ICER decreased as the model time horizon in-
creased and as vaccine coverage increased. The ICER for the CumPop analysis was
always lower than for the Cohort analysis; in the steady-state year, the ICER for the
SSPop analysis was the lowest. CONCLUSIONS: Cost-effectiveness estimates using
data from dynamic transmission models differ depending on the analytic ap-
proach, time horizon, and coverage rate used, with the two population approaches
yielding lower ICERs because they better capture the full population benefit of herd
protection.
IN4
HEALTH CARE RESOURCE UTILIZATION (HCRU) AND COSTS AMONG PATIENTS
TREATED FOR NOSOCOMIAL PNEUMONIA (NP) CAUSED BY METHICILLIN
RESISTANT STAPHYLOCOCCUS AUREUS (MRSA): SECONDARY ANALYSIS OF A
MULTI-CENTER RANDOMIZED CONTROLLED STUDY
Solem CT1, Niederman MS2, Chastre J3, Wan Y1, Gao X1, Myers DE4, Haider S5,
Chambers R4, Li JZ6, Van hout BA7, Stephens JM1
1Pharmerit International, Bethesda, MD, USA, 2Winthrop-University Hospital, Mineola, NY, USA,
3Institut de Cardiologie, Paris, France, 4Pfizer, Inc., Collegeville, PA, USA, 5Pfizer, Inc., Groton, CT,
USA, 6Pfizer, Inc., San Diego, CA, USA, 7University of Sheffield, Sheffield, UK
OBJECTIVES:To compareHCRU and costs between linezolid (LZD) and vancomycin
(VAN) using data from a clinical trial assessing the treatment of NP due to MRSA in
hospitalized adults. METHODS: A post-hoc analysis was conducted using data
from a multi-center trial (Wunderink et al, Clin Infect Dis 2012) to assess length of
treatment (LOT), length of stay (LOS), intensive care unit (ICU) days, mechanical
ventilator (MV) days, and associated costs in NP patients with culture-proven
MRSA [modified intent-to-treat (MITT) cohort]. HCRU was collected through end of
study (EOS; 7-30 days after end of treatment). Frequency and HCRU of moderate/
severe adverse events (MSAE) and renal failure were also assessed. RESULTS:MITT
patients (n448; 224 LZD/224 VAN) had mean (SD) age of 61.8(18.0) years, were
65.6% male, 68.8% white, with 63.1% from North America. At EOS, more LZD vs.
VAN had clinical success (54.8% vs. 44.9%; p0.049), 50.9% remained hospitalized.
No significant differences were found for HCRU or costs (LZD vs VAN):
LOT10.0(3.9) vs. 9.6(4.5) days; MV days8.3(9.3) vs. 8.1(9.1); ICU days10.1(8.8) vs.
10.6(8.7); LOS17.9(9.6) vs. 18.6(9.7) days. 310 patients developed1 MSAE and had
1.7 days longer LOS vs. patients without MSAE. 43 patients (9 LZD/34 VAN,
p0.0001) developed renal failure; renal failure patients had 4.2(p0.004),
3.5(p0.013), and 0.6(p0.74) days longer MV, ICU, and LOS vs. patients without
renal failure. Per patient total costs through EOSwere LZD $45,004 ($25,266) vs. VAN
$44,897 ($25,356). CONCLUSIONS: HCRU and costs were not significantly different
for patients treated with either LZD or VAN during the study. Higher drug acquisi-
tion costs of LZDmay be partially offset by fewer days in ICU and shorter LOS. LOS
is likely underestimated because 50% patients remained hospitalized at EOS
when LOSwas censored. LZD patientsweremore likely to have clinical success and




FDA ACTIONS AGAINST HEALTH ECONOMIC PROMOTIONS, 2002-2011
Neumann PJ, Bliss S
Tufts Medical Center, Boston, MA, USA
OBJECTIVES: To investigate FDA regulatory actions against drug company’s health
economic promotions from 2002 through mid 2011 to understand the types of
economic promotions the Agency considers false or misleading. METHODS: We
reviewed all warning letters and notices of violation (“untitled letters”) issued by
the FDA’s Division of Drug Marketing Advertising and Communications (DDMAC)
to pharmaceutical companies between January 2002 andAugust 2011.We searched
for and analyzed letters containing a violation related to “health economic promo-
tions,” defined according to one of several categories (e.g., implied claims of cost-
savings due to work productivity; economic claims containing unsupported state-
ments about effectiveness or safety). We also collected information on other
factors, such as the indication involved, and whether the letter referenced Section
114 of the Food and Drug Administration Modernization Act (FDAMA), which cre-
ated a different evidentiary standard for health economic promotions made to
formulary committees. RESULTS: Of 280 DDMAC letters sent to pharmaceutical
companies during the study period, 34 (12%) cited an economic violation. Themost
common type (found in 20 letters) was an unsupported implied claim of cost-
savings due to work productivity or functioning. The next most frequent types
included an economic claim containing an unsubstantiated comparative state-
ment of effectiveness, safety, or interchangeability (5 letters) and implied claims of
cost-savings to broader audiences than applicable (4 letters). Economic violations
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have covered various indications, mostly commonly psychiatric disorders (7 let-
ters), pain (5 letters), and cancer (4 letters). No DDMAC letter pertained to FDAMA
Section 114. CONCLUSIONS: The FDA continues to regulate health economic pro-
motions and express concern about certain inappropriate practices, particularly
unsupported work productivity claims and hidden clinical claims (i.e., about effec-
tiveness or safety) embedded in health economic information. More guidance from
the Agency would help clarify what level of substantiation is required for health
economic promotions.
PR2
THE IMPACT OF MINIMALLY INVASIVE SURGICAL TECHNOLOGY ON THE
COSTS OF EMPLOYEE ABSENTEEISM
Epstein AJ, Groeneveld PW, Harhay M, Yang F, Polsky D
University of Pennsylvania, Philadelphia, PA, USA
OBJECTIVES: To assess the impact of six minimally invasive surgical technologies
on worker absenteeism. METHODS: Using national health insurance claims data
(Thomson-Reuters MarketScan Commercial Database) andmatched data onwork-
place absence and short-term disability (MarketScan Health and Productivity Da-
tabase), we identified 37,495 patients aged 18-64 with employer-sponsored health
insurance who underwent either conventional or minimally invasive surgery dur-
ing 2001-2008 for ischemic heart disease (n18,184), uterine fibroids (n12,795),
prostate cancer (n3,466), peripheral vascular disease (n1,856), aortic aneurysms
(n245), or carotid disease (n949). Our primary endpoint was total days absent
from work, measured as the patient-specific difference between days absent dur-
ing the baseline period (-380 days to -15 days from procedure date) and the periop-
erative and post-operative periods (-14 days to  352 days) to account for individ-
ual-specific illness burden and propensity to use medical care. We studied the
similarly-constructed secondary endpoint of the inflation-adjusted sum of (a) the
dollar value of work absences (valued at $344/day for sick/vacation and $241/day
for short-term disability based on prior studies) and (b) the dollar value of health
plan expenditures for medical care. Propensity scores were constructed using year
of surgery, patient age, gender and Elixhauser comorbidities. RESULTS:Minimally
invasive surgerywas associatedwith fewer unadjusted days of workplace absence,
on average, for prostate cancer (-4.3 days), uterine fibroids (-11.4 days), peripheral
vascular disease (-11.9 days), aortic aneurysms (-20.2 days), and ischemic heart
disease (-26.0 days) (p0.001 for all comparisons). Absences were not significantly
different by surgical approach for carotid disease. The unadjusted sumof the dollar
value of absences and medical care spending was lower for minimally invasive
surgery for uterine fibroids (-$1,512, p0.01), aortic aneurysms (-$18,876, p0.06)
and heart disease (-$33,746, p0.001). Results were comparable after propensity
score adjustment. CONCLUSIONS: Minimally invasive procedures frequently re-
duce worker absenteeism by substantial amounts.
PR3
QUALITATIVE ASSESSMENT OF HEALTH-RELATED PRODUCTIVITY
INSTRUMENTS
Tundia NL1, Heaton PC1, Kelton CM2, Hass S3, Fuldeore M3
1University of Cincinnati, Cincinnati, OH, USA, 2University of Cincinnati College of Business,
Cincinnati, OH, USA, 3Abbott Laboratories, Abbott Park, IL, USA
OBJECTIVES: Assessment of lost productivity through health-related productivity
instruments (HRPIs) is useful for pharmacoeconomic research. The aim of this
study was to conduct a systematic review and critique of HRPIs. METHODS:
Through a comprehensive search in the PubMed database using the keywords
“health-related productivity,” “absenteeism,” and “presenteeism,” the following
generic, validatedHRPIswere found: American Productivity Audit andWorkHealth
Interview (APA&WHI), Endicott Work Productivity Scale (EWPS), Health and Labor
Questionnaire (HLQ), Health and Work Performance Questionnaire (HPQ), Health
and Work Questionnaire (HWQ), Health-Related Productivity Questionnaire-Diary
(HRPQ-D), Stanford Presenteeism Scale (SPS), Work Limitations Questionnaire
(WLQ), Work Productivity and Activity Impairment (WPAI), Work Productivity
Short Inventory (WPSI), and Worker Productivity Index (WPI). All HRPIs were
graded on five major and three minor assessment criteria. Major criteria included
(1) lost productivity could be attributed to a specific health-problem; (2) presentee-
ism was measured; (3) absenteeism was measured; (4) lost productivity was ex-
pressed in hours lost; and (5) productivity could be measured for both those in and
out of the labor force. Minor criteria included (1) how perceived impairment was
measured; (2) the minimum recall period required; and (3) whether population
norms existed or could be obtained. RESULTS: All of the HRPIs except HRPQ-D
failed to provide information on at least one major criterion. The SPS, WLQ, WPAI
and WPSI lacked information on 1 major criterion, APA&WHI, HLQ and HPQ on 2
major criteria, EWPS on 3major criteria and HWQ on 4major criteria. The HRPQ-D,
SPS, WLQ, WPAI and WPSI satisfied all or at least 1 major criterion but lacked 1-3
minor criteria. The common major criterion frequently lacking among the SPS,
WLQ, WPAI andWPSI was either household-related productivity loss or valuation.
CONCLUSIONS: Current HRPIs lack comprehensive estimation of lost productivity.
There is an opportunity to develop stronger survey instruments.
PR4
BREAST CANCER MORTALITY RATES BY GEOGRAPHIC REGION, YEARS OF
POTENTIAL LIFE LOST, AND VALUE OF PRODUCTIVITY LOSSES AMONG
WOMEN AGED 20-49 YEARS IN THE UNITED STATES, 1970–2008
Ekwueme DU, Guy GP, Rim SH, Hall IJ, Thomas CC, Fairley TL, Rodriguez J, White A
Centers for Disease Control and Prevention, Atlanta, GA, USA
OBJECTIVES: There are no studies in the United States examining the trends in
mortality rates, years of potential life lost (YPLL), and value of productivity losses
due to breast cancer (BC) amongwomen aged 20-49 years.We examined the trends
in BCmortality rates by geographic region, estimated YPLL and value of productiv-
ity losses by race/ethnicity. METHODS: National mortality data from 1970-2008
were used to calculate age-adjusted mortality rates and rate ratios (RRs). Joinpoint
regression analysis was used to assess changes in trends over time. The YPLL were
calculated to quantify the burden of prematuremortality. The value of lost lifetime
productivity earnings of young women who died of BC in 2008 were used to quan-
tify the expected future value of lost productivity due to premature mortality.
RESULTS: From 1970 through 2008 the age-adjusted mortality rate from BC among
white youngwomenwas 11.45/100,000 and 17.97/100,000 among blacks. Compared
with whites, blacks had substantial higher age-adjusted breast cancer mortality
rates. BC mortality rates vary by geographic region. The decline in BC mortality
rates among blacks has been small (-0.68% per year) compared with whites (-2.02%
per year). During the same period, the total number of deaths associatedwith BC in
young women was 225,866, which accounted for an estimated 7.98 million YPLL.
The estimated total productivity losses attributed to BC in young women who died
in 2008 was $5.49 billion. On average, a young woman who died from BC in 2008
would lose $1.10 million in forgone lifetime earnings. CONCLUSIONS: Although
blacks have substantially higher age-adjusted BC mortality rates, there has been
very little overall change in death rates over time compared to other races. Our
results may implicate the need for focused attention to racial disparities in BC
diagnosis, treatment, and survivorship efforts among specific populations.
PODIUM SESSION III:
RESEARCH ON MEDICAL OUTCOMES QUESTIONNAIRES
QU1
THE DEVELOPMENT AND VALIDATION OF A REVISED VERSION OF THE
MEDICAL OUTCOMES STUDY SLEEP SCALE (MOS-SLEEP-R)
Yarlas AS, White MK, Smith KJ, Bjorner JB
QualityMetric Incorporated, Lincoln, RI, USA
OBJECTIVES: To develop a revised version of the Medical Outcomes Study Sleep
Scale (MOS-Sleep-R), and to evaluate its psychometric properties within a repre-
sentative sample of US adults. METHODS: The MOS-Sleep, developed in the late
1980s, is a 12-item patient-reported instrument measuring sleep outcomes over
the previous 4 weeks, yielding six domain scores – Disturbance, Adequacy, Som-
nolence, Snoring, Awakening to due to shortness of breath/headache, andQuantity
– and two global Sleep Problem Indices (SPI). The MOS-Sleep-R implemented the
following changes: the response option “a good bit of the time” was removed; a
1-week recall period formwas introduced; and 0-100 scores were replaced by stan-
dardized T-scores (mean50, standard deviation10 in the US general population)
with higher scores reflecting better sleep outcomes. Standardization was based on
data from a 2009 US internet-based general population survey. The psychometric
properties of both 1-week and 4-week recall forms of the MOS-Sleep-R were exam-
ined within this development sample. RESULTS: The 1-week and 4-week recall
forms of the MOS-Sleep-R were completed by 2045 and 2033 respondents, respec-
tively. The psychometric properties of the 1-week and 4-week forms were similar.
Patterns of inter-item and item-scale correlations support the scaling assumptions
of the instrument. All multi-item domains, global index scores, and the total scales
showed adequate internal consistency reliability (all Cronbach’s  0.75). Patterns
of correlations between MOS-Sleep-R scores with criterion measures of quality of
life, psychological state, and work and health outcomes indicated adequate con-
vergent validity. Differences in mean scores across groups that differed on the
criterion outcomes supported the instrument’s discriminant validity.
CONCLUSIONS: The MOS-Sleep-R introduces a number of improvements, includ-
ing simplified response sets, the introduction of a 1-week recall form, and norm-
based scoring that enhances interpretability of scores. Both the 1-week and 4-week
recall period forms of the MOS-Sleep-R demonstrated good reliability and validity.
QU2
CROSS-CULTURAL PSYCHOMETRIC EVALUATION OF THE ENSEMBLE MDS
Bushnell DM1, Mccarrier KP2, Martin ML2, Paczkowski R3, Shen W3, Buesching D3
1Health Research Associates, Inc., Mountlake Terrace, WA, USA, 2Health Research Associates,
Inc., Seattle, WA, USA, 3Eli Lilly and Company, Inc., Indianapolis, IN, USA
OBJECTIVES: The ENSEMBLE MDS is a battery of phenotypic patient-reported in-
struments administered at baseline in clinical studies. The component measures
assess potential predictors (Self-Reported Health Status (SRH), Total Illness Burden
Index (TIBI), Patient Health Questionnaire-4, Depression Diagnosis, Perceived
Stress Scale) or effect modifying factors of clinical outcomes and/or treatment
response (MacArthur Perceived Status Ladder, MacArthur Income, Barratt Simpli-
fied Measure of Social Status, Perceived Social Support Scale (SS-5). This report
furthers the initial validation conducted in the United States by evaluating the
reproducibility and construct validity outside the United States. METHODS: The
ENSEMBLE MDS and other assessments (MOS SF-36, EQ-5D, Life Orientation Test-
Revised (LOT-R), items on illness/bed days and doctor visits) were administered to
a sample of adults with depression, type 2 diabetes, or rheumatoid arthritis in
Germany (n61), Spain (n61) and Singapore (n56, Simplified Chinese). Partici-
pants completed the battery on paper and returned one-week later to complete a
retest. Test-retest reproducibility was assessed using the intraclass correlation
coefficient (ICC); convergent validity by Pearson correlations between MDS instru-
ments and components of the SF-36 and EQ-5D, with hypothesized relationships
significant at r0.30; and known-groups tested using tertiles of the LOT-R, doctor
visits and illness days. RESULTS: The mean age of the participants was 5513
years, 63% were female, 66% were married/living with partner. Between 85% and
100% completed MDS instruments at the retest (mean 6.70.6 days). The ICCs for
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